- Home
- ANVS vs FAAS Comparison
ANVS vs FAAS Comparison
Compare ANVS & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- FAAS
- Stock Information
- Founded
- ANVS 2008
- FAAS 2021
- Country
- ANVS United States
- FAAS Indonesia
- Employees
- ANVS N/A
- FAAS N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- FAAS
- Sector
- ANVS Health Care
- FAAS
- Exchange
- ANVS Nasdaq
- FAAS NYSE
- Market Cap
- ANVS 54.6M
- FAAS 48.2M
- IPO Year
- ANVS 2020
- FAAS N/A
- Fundamental
- Price
- ANVS $2.64
- FAAS $0.57
- Analyst Decision
- ANVS Strong Buy
- FAAS
- Analyst Count
- ANVS 5
- FAAS 0
- Target Price
- ANVS $30.25
- FAAS N/A
- AVG Volume (30 Days)
- ANVS 570.5K
- FAAS 20.3M
- Earning Date
- ANVS 08-14-2025
- FAAS 01-01-0001
- Dividend Yield
- ANVS N/A
- FAAS N/A
- EPS Growth
- ANVS N/A
- FAAS N/A
- EPS
- ANVS N/A
- FAAS N/A
- Revenue
- ANVS N/A
- FAAS $57,730,593.00
- Revenue This Year
- ANVS N/A
- FAAS N/A
- Revenue Next Year
- ANVS N/A
- FAAS N/A
- P/E Ratio
- ANVS N/A
- FAAS N/A
- Revenue Growth
- ANVS N/A
- FAAS 38.16
- 52 Week Low
- ANVS $1.11
- FAAS $0.16
- 52 Week High
- ANVS $17.88
- FAAS $8.49
- Technical
- Relative Strength Index (RSI)
- ANVS 54.28
- FAAS 48.67
- Support Level
- ANVS $2.73
- FAAS $0.57
- Resistance Level
- ANVS $3.08
- FAAS $0.69
- Average True Range (ATR)
- ANVS 0.32
- FAAS 0.18
- MACD
- ANVS -0.06
- FAAS -0.04
- Stochastic Oscillator
- ANVS 29.41
- FAAS 9.73
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.